Operations as a competitive advantage in biotechnology

McKinsey

Esteban Santos, executive vice president for operations at Amgen, explains how the company is using operations to support innovation. Insights on Pharmaceuticals & Medical Products

How biotechs can rethink their strategies after the market downturn

McKinsey

Insights on Life Sciences Health Care BiotechnologyBiotech stocks have taken a hit, but the sector will probably rebound. Companies can navigate the downturn by scrutinizing cash management and financing and rethinking paths to long-term value creation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Building pharma pipelines using a socioeconomic lens

McKinsey

Insights on Life Sciences Biotechnology InnovationHarnessing advances in science and technology can deliver transformative therapies faster while reducing the socioeconomic burden of disease.

Building a global biotech: Taking a first-time launch into international markets

McKinsey

Insights on Life Sciences Biotechnology Globalization StrategyEstablishing an international presence with a first launch is a challenge, but learning from others’ experiences can help biotechs avoid missteps and maximize their chances of success.

Forward Thinking on the Bio Revolution with Jason Kelly and Dr. Michelle McMurry-Heath

McKinsey

Insights on Pharmaceuticals & Medical Products BiotechnologyThe leaders of Gingko Bioworks and the BIO organization discuss the future of biological technologies, from developing vaccines faster to changing how we produce food.

An inflection point for biosimilars

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology PharmaceuticalsWith rising US adoption, biosimilars are gathering even more momentum. Successful companies will innovate their commercial models, rethink their portfolio management, and accelerate their R&D.

Can European biotechs achieve greater scale in a fragmented landscape?

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology EuropeWorld-class science and innovation need to be matched with stronger scale-up capabilities and a broader funding base if Europe is to emerge as a leader in biotech.

Gene-therapy innovation: Unlocking the promise of viral vectors

McKinsey

Insights on Pharmaceuticals & Medical Products Pharmaceuticals BiotechnologyViral-vector gene therapies show great promise, but the full extent of their clinical impact in the long term is not yet certain. Success depends on innovative solutions that remain under development.

Precision medicine in practice: Strategies for rare cancers

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology Pharmaceuticals Oncology/CancerThe small number of people with rare diseases raises challenges for the development and launch of all therapies for such conditions, but rare cancers face extra barriers to widespread treatment.

Infographic: Biotech hot spots in a fragmented European landscape

McKinsey

Insights on Pharmaceuticals & Medical Products BiotechnologyWe mapped out 1,382 biotechs based in Europe and some interesting themes emerged.

Infographic: Building the European biotech sector with world-class science and innovation

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology EuropeEurope is a powerhouse in scientific publishing with roughly twice the output of the United States and three times that of China.

Infographic: Biotech in Europe: Driving the next act

McKinsey

Insights on Pharmaceuticals & Medical Products BiotechnologyHow can biotechs and investors succeed in the future? To scale up innovation, industry stakeholders need to focus on several key areas.

Infographic: Capital landscape for European biotechs is maturing, but it continues to trail the United States

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology EuropeEurope’s biotech sector has made meaningful progress in attracting capital. However, raising more capital will be essential to the continued growth of this sector.

Infographic: Biotech in Europe: Driving the next act

McKinsey

Insights on Life Sciences BiotechnologyHow can biotechs and investors succeed in the future? To scale up innovation, industry stakeholders need to focus on several key areas.

Piloting a biotech leader to greater growth

McKinsey

Growth in a dynamic biotechnology industry requires empowering teams, making real-time adjustments, and shifting the mind-set to accelerate toward the end goal. Marketing & Sales Insights

Infographic: The McKinsey Biotech Innovation Index

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology EuropeEurope may be catching up with the United States in biotech innovation and funding. Its overall score on the Biotech Innovation Index improved by 20 percent in 2015–17 and 2018–20.

The new world of patient engagement

McKinsey

The CEO of Acorda Therapeutics, Ron Cohen, explains how the biotechnology company’s relationship with patients is changing and what that means. Our Insights

Weekend fun – read a good book: “Makers”

Killer Consultant

The story makes you learn about important innovation trends, like 3D printing, open innovation, crowdsourcing, biotechnology body enhancing, etc. I’ve been enjoying this book tremendously over the last days, thought I’d let you know about it. The book is “Makers” by Cory Doctorow.

Weekend fun – read a good book: “Makers”

Killer Consultant

The story makes you learn about important innovation trends, like 3D printing, open innovation, crowdsourcing, biotechnology body enhancing, etc. I’ve been enjoying this book tremendously over the last days, thought I’d let you know about it. The book is “Makers” by Cory Doctorow.

Top 10 Consulting Firms in San Francisco

Management Consulted

San Francisco, and the Bay Area in general, is famous for its long history of leadership in computing, semiconductors, software, biotechnology, the Internet and other innovation-based industries. C1 Consulting: A boutique life-sciences consulting firm committed to helping pharmaceutical and biotechnology clients.

Fourth Industrial Revolution: Robots, Artificial Intelligence Will Destroy 5.1 Million Jobs by 2020

MishTalk

The Fourth Industrial Revolution includes developments artificial intelligence, robotics, nanotechnology, 3-D printing, genetics, and biotechnology. Fourth Industrial Revolution Coming A new study on the " Future of Jobs " by the World Economic Forum at Davos claims a Fourth Industrial Revolution is Coming. Although no industrial revolution has ever destroyed jobs, the study concludes a net 5.1 million jobs will vanish in the world's 15 leading countries.

Framework for Understanding Market Tops and Bottoms

MishTalk

One area that currently is frothy is the biotechnology sector. Last week I received an excellent article from Variant Perception on "Market Tops", and have permission to excerpt some of it. Here is a link to the summary page of Understanding Market Tops. What follows are a few snips from the full report. Framework for Understanding Tops In the following table, we summarize the signs of market bottoms and tops.

The Brattle Group Interviews and Culture

Management Consulted

In healthcare, the firm focuses on the enormous and fast-growing sectors of pharmaceuticals, medical devices, and biotechnology. THE BRATTLE GROUP. Today we take a look at a boutique consulting firm you may not have heard of, The Brattle Group. Founded in 1990, The Brattle Group offers answers to economic, regulatory and financial questions posed by corporations, law firms and governments around the globe.

Do You Have the Right Decision Making Culture?

LSA Global

Examples of common fact-based decision making cultures include biotechnology, finance, and medical device companies. Decision Making Culture. With the advancements in data analytics and artificial intelligence, more leaders are asking about the pros and cons of a fact-based vs. an intuition-based decision making culture. Because it is the responsibility of leaders to build effective decision making capabilities throughout their organization. Defining Workplace Culture.

Research: The Average Age of a Successful Startup Founder Is 45

Harvard Business

However, young people are less common in other industries such as oil and gas or biotechnology, where the average age is closer to 47. Patricia de Melo Moreira/bloomberg/Getty Images. It’s widely believed that the most successful entrepreneurs are young. Bill Gates, Steve Jobs, and Mark Zuckerberg were in their early twenties when they launched what would become world-changing companies. Do these famous cases reflect a generalizable pattern? VC and media accounts seem to suggest so.

In Memory of Spock: Live Long and Prosper; Is He or Isn't He? Fish Tomatoes, Hand Transplants, Sci-Fi vs. Reality

MishTalk

But the agency was officially mandated with promoting biotechnology and bent over backwards to push GMOs onto the market. One of my favorite characters in TV history was Star Trek''s "Spock". Yesterday, Leonard Nimoy, Spock of ‘Star Trek,’ Died at 83.

The Promise and Challenge of Big Data for Pharma

Harvard Business

From our unique vantage points at Genentech , a leading biotechnology company with a major data science practice, and The Data Incubator , a data-science education company that places and trains data scientists , we have seen how the pharmaceuticals industry has leveraged big data for some potentially revolutionary advances and the challenges it has faced along the way.

Why It’s So Hard to Train Someone to Make an Ethical Decision

Harvard Business

Take the decision of Sam Waksal, the former CEO of the emerging biotechnology company ImClone Systems. One of the conundrums of ethical decision making is that many moral decisions that are quite straightforward — even easy — to resolve in a classroom or during training exercises seem far more difficult to successfully resolve when confronted during actual day-to-day decision making.

The Reason Silicon Valley Beat Out Boston for VC Dominance

Harvard Business

In contrast, New England has increasingly become a hub for ventures in life sciences; the first three-quarters of 2016 saw almost 60% of VC investments in New England go to ventures in biotechnology and medical devices. Despite the East Coast roots of technology entrepreneurship and venture capital (VC), by the 1990s Silicon Valley had gained a major advantage over the Cambridge-Boston area. In 1995 Silicon Valley’s share of all VC investments in the U.S.

Companies Can Address Talent Shortages by Partnering with Educators

Harvard Business

“Together, in response to industry demand, we’re creating a dedicated pipeline of skilled biomanufacturing professionals,” said Bruce Van Dyke, chair of Quincy’s Biotechnology and Good Manufacturing Practice program, in a recent interview with us. Bernhard Lang/Getty Images. Although it’s hard to pinpoint when skills shortages became the norm in the U.S.,

Teams Solve Problems Faster When They’re More Cognitively Diverse

Harvard Business

We worked with a startup biotechnology company. Looking at the executive teams we work with as consultants and those we teach in the classroom, increased diversity of gender, ethnicity, and age is apparent. Over recent decades the rightful endeavor to achieve a more representative workforce has had an impact. Of course, there is a ways to go, but progress has been made.

How to Get Yourself Invited to Important Meetings

Harvard Business

She was on the legal compliance team at a fast-growing biotechnology company. MINCHU/Getty Images. In a work culture with too many meetings, we often look for tactics to get out of meetings. But sometimes you need to get into a meeting, perhaps because the decisions made there will have implications for you or your team, or maybe because you feel you’ve been left out of important discussions.

Why Boards Aren’t Dealing with Cyberthreats

Harvard Business

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., One of the greatest challenges facing boards today is the one directors feel least prepared for: cybersecurity. Yahoo’s disclosure in December of what could be the largest data breach in history was hardly an isolated incident. Indeed, the Guardian dubbed 2016 the “year of the hack,” and cyberthreats are increasingly common across all sectors.

Why Women Feel More Stress at Work

Harvard Business

In one study, female and male MBA students were paired and asked to negotiate the purported purchase of a biotechnology plant. Everyone in today’s supercharged workplaces experiences stress. Yet executive and professional women consistently experience more stress, anxiety, and psychological distress than do men.

Innovation Should Be a Top Priority for Boards. So Why Isn’t It?

Harvard Business

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., Jason Jaroslav Cook Creative/Getty Images. Corporate directors and executives alike recognize that today’s pace of change continues to accelerate and that firms need to innovate to stay ahead. But are boards doing enough to support innovation, as they should? We conducted a survey of over 5,000 board members from around the world to find out.

7 Charts Show How Political Affiliation Shapes U.S. Boards

Harvard Business

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., Are corporate boards as polarized politically as the general population? That’s one of the questions we asked ourselves as we conducted a survey of directors of public and private companies headquartered in the United States.

So Many M&A Deals Fail Because Companies Overlook This Simple Strategy

Harvard Business

The rationale for this approach is highlighted when you compare, for example, the different approaches to M&A employed by a number of legacy pharmaceutical companies and by some relatively newer players in the biotechnology industry. We have all seen or heard of high-profile cases where M&A deals didn’t work out. AOL–Time Warner, HP-Compaq, Quaker-Snapple — these are just some of the big ones.

Innovative Companies Get Their Best Ideas from Academic Research — Here’s How They Do It

Harvard Business

In virtually every advanced field, whether it’s information technology, biotechnology, agriculture, or renewable energy, America holds a leading position. vincent tsui FOR HBR. Since World War II, the U.S. has been an innovation superpower. Other nations may challenge in one field or another, but no one can match its depth and breadth.

Technology Progresses When Business, Government, and Academia Work Together

Harvard Business

” His organization is trying to change that by reaching out to all areas of the ecosystem — “we include academic institutions, venture capitalists, and industrial players ranging from big pharma to startup biotechnology firms because we believe that the best science happens when we get everybody’s perspective, Depinho says.” By the mid-1980’s, the American semiconductor industry seemed like it was doomed.

Why Mexico’s Economy Doesn’t Depend on the Next U.S. President

Harvard Business

Intense biotechnology research and development activities at some of the country’s universities (and their research farms) have raised the complexity and level of the industry’s outputs. The Mexican peso initially fell 13% in trading after Republican Donald Trump won the U.S. presidency in a surprise result over Democratic nominee Hillary Clinton. It was the biggest drop for the currency since an economic crisis in 1994.